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Abstract  
Amiodarone remains the mostly frequently used antiarrhythmic in clinical practice and is 
most often used to maintain normal sinus rhythm in patients with atrial fibrillation who 
have failed a rate control strategy. Amiodarone has superior efficacy over other 
antiarrhythmics, lower risk of torsades de pointes, and a better cardiovascular safety 
profile in patients with structural heart disease. However, amiodarone is associated with 
notable non-cardiac toxicities affecting the thyroid, lungs, eyes, liver, and central 
nervous system. Since 2000, clinicians have been advised to follow amiodarone 
monitoring guidelines provided by the Heart Rhythm Society. Adherence to these 
recommendations in clinical practice is, however, suboptimal. Pharmacists play a major 
role in ensuring the safe and effective use of medications, particularly high-risk 
medications such as amiodarone. This qualitative review details the evidence 
supporting the role of pharmacist-led amiodarone monitoring services (AMS) in 
improving adherence to amiodarone monitoring guidelines and identifying adverse 
effects. Five studies were identified and, overall, these programs had a favorable impact 
on improving adherence to guideline-recommended monitoring standards for 
amiodarone. The available evidence is limited by the significant variations in study 
designs, outcome definitions, lack of patient randomization, and limited generalizability. 
Nevertheless, available studies suggest pharmacist-led AMS may improve adherence to 
recommended monitoring guidelines and identification of amiodarone-related adverse 
effects. Further study is warranted to demonstrate whether or not these services impact 
the overall quality of care provided to patients receiving amiodarone, which might justify 
broader implementation. 
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Introduction 
Atrial fibrillation (AF) remains the most frequently observed cardiac arrhythmia in 
clinical practice with an estimated prevalence of nearly 6 million in the United States. 
Some projections estimate the prevalence of AF will double by 2050.1 Although a rate 
control strategy is often preferred, antiarrhythmic medications are indicated in patients 
with significant symptoms despite satisfactory rate control.2 Recent trends suggest an 
increase in the application of a rhythm control strategy as evident in the rise of AF 
ablation procedures, and a 2% per year increase in antiarrhythmic prescriptions.3, 4  
Amiodarone is a multi-channel blocker (potassium, sodium, and calcium) and 
noncompetitive alpha- and beta-blocker. Although not approved by the Food and Drug 
Administration (FDA) for AF, amiodarone remains the most frequently prescribed 
antiarrhythmic used for AF, accounting for approximately 45% of all antiarrhythmic 
prescriptions.4 This is primarily due to its superior efficacy in maintaining normal sinus 
rhythm (NSR) over other antiarrhythmics and demonstrated cardiovascular safety in 
patients with structural heart disease.2 However, amiodarone is notoriously associated 
with multiple non-cardiac multi-organ toxicities. As such, the Heart Rhythm Society 
(formerly the North American Society of Pacing and Electrophysiology) published the 
first amiodarone monitoring guidelines in 2000,5 which were most recently updated in 
2015.6 These guidelines are summarized in Table 1. 
Adherence to amiodarone monitoring guidelines in clinical practice has been 
suboptimal. A retrospective cohort study at 10 health maintenance organizations found 
that only half of the 1,055 patients on amiodarone received the recommended 
monitoring for both liver and thyroid toxicity.7 The available evidence also suggests that 
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adherence to baseline monitoring is much higher than follow-up monitoring.8 This is 
problematic when the risk of amiodarone-related toxicities increases with longer 
duration of use. Furthermore, while a majority of patients receiving amiodarone 
experience an adverse effect in the first year of therapy, one-third of these may be 
preventable with appropriate long-term monitoring.9  
One suggested approach to improving the chronic monitoring of patients 
receiving amiodarone therapy has been the utilization of Amiodarone Monitoring 
Services (AMS). Considering the role pharmacists play in ensuring the safe and 
effective use of medications, it is no surprise that many AMS are pharmacist-led. The 
objective of this qualitative review is to summarize the available evidence evaluating the 
effectiveness of pharmacist-led AMS in improving adherence to amiodarone monitoring 
guidelines and identification of previously unrecognized adverse effects.  
Methods  
Search Strategy 
We conducted a search of English language publications from database 
inception through October 30, 2015 using PubMed, CINAHL (EBSCOHost), Web of 
Science, Cochrane Library and ProQuest Dissertations & Theses. The search was 
divided into three concept groups, including the terminology used to describe 
“amiodarone,” “pharmacists,” and “drug monitoring.” Medical Subject Headings (MeSH) 
and equivalent controlled vocabulary and keywords were utilized in each database as 
appropriate. Additionally, a reference list of the retrieved publications was searched to 
identify publications not identified in the database search. The search results and 
process of screening and study selection is illustrated in Figure 1. 
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Studies were included if they described an AMS that included pharmacists and 
reported outcomes that included adherence to amiodarone monitoring guidelines and/or 
incidence of patients that experienced a previously unrecognized amiodarone-related 
adverse event. Published studies of multidisciplinary models were included if the role of 
the pharmacist was clearly described and a primary component of the intervention. For 
purposes of this review, pre-post studies were considered acceptable. Broad drug 
monitoring programs that did not focus on amiodarone were excluded. Abstracts, letters 
to the editor, and editorials were also excluded from this review.  
Results 
Two investigators (DD, MK) independently identified five articles that met our 
inclusion criteria. A summary of included studies is listed in Table 2. Study sites 
included outpatient clinics at an academic medical center,10 integrated healthcare 
systems,11-13 and a private, university-affiliated cardiology clinic.14 The respective study 
designs included three unmatched retrospective cohort studies11-13 and two uncontrolled 
pre-post studies.10,14 Adherence to amiodarone monitoring guidelines was a primary 
clinical outcome for all of the studies,10-14 while the reporting of amiodarone-related 
adverse effects was reported in all but one study.15  
Study methods included physician-pharmacist protocols or algorithms,11,14 
electronic tracking tools,13 and face-to-face outpatient clinic visits.10,11,14 Pharmacists’ 
primary role in each study involved ensuring monitoring parameters were obtained or 
scheduled. Additional interventions included recommending antiarrhythmic dose 
adjustments, identifying and making recommendations for managing drug-drug 
interactions and/or adverse drug reactions, obtaining medication histories, and providing 
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patient education. Several of the monitoring programs were interdisciplinary 
collaborative-care models that included other healthcare professionals, such as 
electrophysiologists,10 general cardiologists,13,14 and registered nurses,14 but 
pharmacists served in a primary role in each of these.  
Evaluation of Clinical Outcomes 
Retrospective Cohort Studies  
Three studies evaluated adherence to amiodarone monitoring guidelines by 
comparing patients followed by an AMS to a retrospective cohort of patients that did not 
participate in the AMS (i.e., usual care). The study follow-up period after implementation 
of the AMS was 12 months for each of these studies. Overall, patients followed by the 
AMS had significantly higher rates of adherence to the recommended amiodarone 
monitoring guidelines compared to usual care. Adherence to the recommended 
baseline monitoring parameters varied between studies, but generally occurred in less 
than 50% of the patients.11-13 
  Graham et al11 reported no difference between groups at baseline, except for 
eye exams, which occurred more frequently in the intervention group. Johnson et al13 
observed adherence to baseline monitoring of alanine transaminase (ALT) and 
electrocardiogram (ECG) was significantly higher in the intervention group compared to 
usual care. Spence et al.12 reported baseline monitoring of ALT, thyroid stimulating 
hormone (TSH), pulmonary function tests (PFT), and chest x-ray occurred more 
frequently in the intervention group. All three studies reported significantly higher 
adherence to follow-up liver function test (LFT) monitoring in the intervention group 
compared to usual care, although the recommended monitoring of LFT in the study by 
7 
Systematic Review of Amiodarone Monitoring Services 
 
Graham et al10 occurred twice as frequently as the studies by Johnson et al.13 
Incidence of identified adverse events was reported in two studies.11,13 Graham 
et al.11 reported 17% of patients in the AMS group had a documented TSH elevation, 
compared to 10% of patients in the control group (p=0.23). Thyroid abnormalities were 
also the most common adverse event reported by Johnson et al,13 but the overall rate of 
confirmed amiodarone-related adverse events was significantly lower in patients 
followed by the AMS (5.4% vs. 9.3%; p=0.031). 
Longitudinal Studies  
 Two studies10,14 analyzed the effectiveness of the AMS using a pre/post-
intervention study design. Sanoski et al9 reported that recommended laboratory 
monitoring occurred in only 23% of patients before referral to the AMS. Before enrolling 
in the AMS, the patients were followed by their primary physician for a mean of 16.3 + 
25.5 months. After a mean follow-up of 9.2 + 5.5 months in the AMS, 90% of patients 
received recommended laboratory monitoring (p<0.001). Overall adherence rates to 
amiodarone monitoring parameters were not reported by Tafreshi et al,14 but the study 
did report an increase in PFT monitoring from only 5% at baseline to 77.5% after 
referral to the AMS.  
Previously unrecognized adverse effects were identified, post-referral to the 
AMS, in 35% and 19% of patients in the studies by and Sanoski et al10 and Tafreshi et 
al,14 respectively. The most commonly detected adverse effects in both studies were 
thyroid-related and pulmonary toxicities. Unrecognized thyroid abnormalities were 
reported in 13% of patients by Sanoski et al10 and 9% of patients by Tafreshi et al.14 
Pulmonary fibrosis was diagnosed in 6.7% of the patients followed by the AMS in the 
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study by Sanoski et al.10 Unspecified pulmonary toxicity was recognized in 9.1% of the 
patients in the Tafreshi et al study.14 
Discussion 
 An extensive search of available literature revealed five studies that evaluated 
the impact of pharmacist-led AMS on adherence to amiodarone monitoring guidelines, 
and identification of previously unrecognized adverse effects. The available evidence 
favors the use of pharmacist-led AMS to ensure patients receiving chronic amiodarone 
therapy are appropriately monitored. Greater involvement of pharmacists in the 
monitoring of patients receiving long-term amiodarone therapy could improve the safe 
use of this high-risk medication.   
Interestingly, our review found that thyroid abnormalities and pulmonary toxicity 
were the most commonly observed amiodarone-related toxicities. Thyroid function 
abnormalities are common with amiodarone and of concern given the known effects 
these abnormalities have on cardiac contractility and output, blood pressure, and 
arrhythmia pathogenesis.15 One study found a 60% increased risk of mortality in heart 
failure patients with an ejection fraction <35% and baseline or new-onset abnormal 
thyroid function during the study follow-up period.16 Unsurprisingly, new onset thyroid 
abnormalities were nearly four times more common in patients receiving amiodarone.16 
These data highlight the importance of thyroid function monitoring in patients receiving 
amiodarone as early identification and treatment may prevent fatal adverse sequelae in 
patients with cardiovascular disease.  
While one of the studies included in our review10 specifically reported the rates of 
pulmonary fibrosis, others were more vague and simply reported rates of general 
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pulmonary toxicity. This is important considering amiodarone-induced pulmonary toxicity 
can manifest itself in various ways with the most serious being pulmonary fibrosis 
associated with acute respiratory distress syndrome.17 While the mortality rate of 
amiodarone-induced pulmonary fibrosis has been reported to be as high as 10%, an 
early diagnosis may improve survival in these patients.5 Thus, a high clinical suspicion 
in a patient with unexplained dyspnea should warrant immediate evaluation. Appropriate 
follow-up may help identify those with possible pulmonary toxicity before the 
development of irreversible pulmonary fibrosis.  
  As demonstrated in this study, current amiodarone monitoring practices remain 
suboptimal, potentially due to the fractured care across general and specialty 
caregivers. Team-based models of care including pharmacists, have been shown to 
improve cardiovascular clinical outcomes,18 reduce preventable adverse effects,19 and 
readmission rates.20 Despite the potential benefit of such collaborative practice models, 
broader inclusion of pharmacists in medical practices is limited by lack of a formalized 
reimbursement structure.21 The case could be made that ensuring proper monitoring of 
amiodarone, and possibly other antiarrhythmics, may have a favorable impact on 
reducing healthcare costs. A rhythm control approach costs approximately $5,000 more 
per person than rate control and has been linked to a higher rate of hospitalizations.22 
The advent of efforts to restructure payment models based on quality of care in the 
private sector may provide financial justification for broader implementation of 
pharmacist-led AMS. Ultimately, the economical feasibility of AMS is beyond the scope 
of this review and warrants further study. 
The following limitations should be considered when interpreting the findings of 
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this qualitative review. We found significant variations in study designs and outcome 
definitions, and none of the studies randomized patients. The retrospective nature of 
these studies does not rule out the possibility of missing data and inability to capture 
data outside of integrated health care systems to confound these findings. For these 
reasons, it was not feasible to combine results and perform a meta-analysis. 
Additionally, the available amiodarone monitoring guidelines are not evidence-based, in 
the sense that no studies have tested whether prospective monitoring actually prevents 
amiodarone-related adverse effects. With that said, a notable number of patients in 
these studies required dose adjustments, therapy discontinuation, and had previously 
unrecognized and new onset adverse effects due to amiodarone. This suggests that 
prospective monitoring may be an effective means to mitigate the adverse effects 
associated with amiodarone. 
Conclusion 
 To our knowledge, this is the first compilation of available studies evaluating the 
effectiveness of pharmacist-led AMS. Our review of the literature identified five studies 
of pharmacist-led AMS to improve amiodarone monitoring and identify potential 
amiodarone-related adverse effects. This preliminary evidence suggests these 
programs can improve adherence to amiodarone monitoring guidelines and recognition 
of amiodarone-related adverse effects. However, the study quality was generally poor 
and we found no prospective, randomized studies. A national shift toward quality-based 
payment models may justify further consideration of pharmacist-led AMS to monitor 
patients receiving chronic amiodarone therapy, but additional studies are warranted. 
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